Favorable treatment outcome with neutralizing anti-transforming growth factor beta antibodies in experimental diabetic kidney disease.
Han
D C
DC
Penn Center for Molecular Studies of Kidney Diseases, Department of Medicine, University of Pennsylvania, School of Medicine, Philadelphia 19104-6144, USA.
Ziyadeh
F N
FN
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000473:pathology; D003928:Diabetic Nephropathies / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D006984:Hypertrophy; D007668:Kidney / Q000473:pathology; D051379:Mice; D016212:Transforming Growth Factor beta / Q000276:immunology* / Q000502:physiology
D000911:Antibodies, Monoclonal; D016212:Transforming Growth Factor beta